asco2020_mgd013phase1
Encouraging Activity Observed With MGD013 In Various Tumor Types
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. - Abstract - Europe PMC
Frontiers | Immune Checkpoint Inhibitors in the Treatment of HCC
Clinical landscape of LAG-3-targeted therapy - Immuno-Oncology and Technology
Document
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges - ScienceDirect
Multispecific antibody formats in clinical trials by structure, mode of... | Download Scientific Diagram
A Phase 1, Open-Label Study of MGD013 (Tebotelimab), a Bispecific DART® Molecule Binding PD-1 and LAG-3, in Patients with Relap
![Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Cholangiocarcinoma,%20Neoplasms,%20Malignant%20Solid%20Neoplasms,%20Refractory%20Malignant%20Solid%20Neoplasm,%20Refractory%20Cholangiocarcinoma:%0A%0ACeralasertib%20for%20Cholangiocarcinoma.png?md=1 "Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power")
Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 | Molecular Cancer | Full Text
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Frontiers | Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective ...
IJMS | Free Full-Text | LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors | HTML
IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer | HTML
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups | Nature Immunology
Bispecific Antibodies: The Next Generation of Immunotherapy
PARP inhibitors in gastric cancer: beacon of hope | Journal of Experimental & Clinical Cancer Research | Full Text
The state of the art of bispecific antibodies for treating human malignancies | EMBO Molecular Medicine
PDF) 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
2020 ASCO Immuno-Oncology Abstracts | Journal of Clinical Oncology
A Phase 1, First-in-Human, Open-label, Dose Escalation Study of MGD013, a Bispecific DART® Protein Binding PD-1 and LAG-3 in P
MacroGenics, NanoString to Co-Develop Immuno-Oncology Biomarkers
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors - JTO Clinical and Research Reports
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges - ScienceDirect
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells - Xie - 2021 - Advanced Science - Wiley Online Library
![Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Cholangiocarcinoma,%20Intrahepatic%20Cholangiocarcinoma:%0A%0ADexamethasone%20for%20Cholangiocarcinoma.png?md=1 "Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power")
Top 10 Cholangiocarcinoma Clinical Trials [2022 Studies] | Power
![PDF] LAG-3: from molecular functions to clinical applications | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f65965a5f770156677f7e00913df51cd088596a8/6-Table1-1.png "PDF] LAG-3: from molecular functions to clinical applications | Semantic Scholar")
PDF] LAG-3: from molecular functions to clinical applications | Semantic Scholar
